Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Matritech assesses breast cancer screening test:

This article was originally published in Clinica

Executive Summary

Matritech has begun a multicentre clinical trial in the US to investigate whether its NMP66 blood test for breast cancer has potential as a screening tool for the disease. Researchers will assess how well the test detects breast cancer, differentiates between benign and malignant lesions and identifies patients with normal mammograms, says the Newton, Massachusetts company, which has begun recruiting patients for the study. The trial will be conducted at six centres and will enrol around 1,000 patients.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT071426

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel